Malvern Instruments acquires nanoparticle characterization company NanoSight
Malvern Instruments Ltd (Malvern, UK), a leading global provider of instrumentation and expertise for materials and biophysical characterization, has acquired nanoparticle characterization company NanoSight Ltd (Amesbury, UK). The acquisition was completed on Friday 27 September 2013.
NanoSight has developed and commercialized a unique and patented technology, Nanoparticle Tracking Analysis (NTA). The company's instrumentation and software enable the rapid and simultaneous multi-parameter analysis and characterization of many different types of nanoscale particles. With their ability to analyze particle size, concentration, zeta potential and aggregation, NanoSight systems are closely aligned with Malvern's market-leading Zetasizer range, extending Malvern's solutions for those working at the nanoscale.
Currently the largest applications area for NTA is in life sciences, for the measurement of biological nanoparticles, where one of the most exciting and rapidly expanding fields is exosomes. These are intercellular messengers whose quantity and biochemical composition reflect the disease status of an individual. NanoSight technology uniquely provides quantitative detection and characterization capabilities to make exosomes a viable proposition as biomarkers for drug discovery, disease prognosis, diagnosis and monitoring, as well as personalized medicine.
Paul Walker, Managing Director of Malvern Instruments, said: "NanoSight is a real entrepreneurial success story and I am delighted to be welcoming the NanoSight team to Malvern. NanoSight has grown every year since it was established in 2002 and has ambitious plans for the future. We will be providing the investment and support needed to continue this drive forward and are absolutely committed to developing the NanoSight brand within the Malvern portfolio.
"NanoSight's unique technology has become accepted in laboratories around the world and is widely cited in research publications. With rapid advances in nanomaterials and the life sciences, in biopharmaceuticals especially, the demand for new technologies to answer continually evolving analytical challenges has never been greater. This is a very exciting time and by bringing together complementary, leading edge technologies, Malvern continues to focus on delivering the analytical tools which laboratories so urgently need."
Jeremy Warren, CEO of NanoSight, said, "We have always seen Malvern as the clear leader in our sector, and the exemplar of what we wish to become. The plans we have are ambitious and exciting, and the support and reach of the Malvern organization will allow us to grow more rapidly than we could alone. I am sure that this change will bring opportunity to both our business and our colleagues. Malvern is our natural home."
NanoSight employs around 50 people worldwide and will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team. Malvern's direct sales operations in key geographies and wider global presence will be used to make the NanoSight instruments and aftersales support even more accessible to a wider market.
more about Malvern Instruments
more news from Malvern Instruments
more about NanoSight
more news from NanoSight
A Queen's Award for Enterprise for International Trade 2012 has been awarded to NanoSight, the UK's fastest growing biotechnology company
Malvern specialist to explore use of Nanoparticle Tracking Analysis for characterizing extracellular vesicles at ISEV 2014
Published papers endorse NanoSight technology
NanoSight joins the EU Methods List relating to "Nanomaterials"
Nanoparticle Tracking Analysis technology facilitates cancer metastasis research
The Science and Engineering Institutes, Singapore, are using Nanoparticle Tracking Analysis to characterize exosomes.
Leading UK scientist, Dr Andrew Shuttleworth, joins NanoSight board as Director of Diagnostic Sciences
Duke University uses Nanoparticle Tracking Analysis to characterize "nanoconstructs" for biomedical applications
Radboud University Nijmegen applies nanoparticle tracking analysis from NanoSight to study molecular machines
The NanoChemistry group at the Technical University of Denmark (DTU) uses NanoSight's NTA system for nanoparticle characterization
NanoSight wins Technology World's 2011 Business Innovation Award
Landmark publication reports potential of exosomes as biomarkers for early disease detection using NanoSight's NTA technology
The University of St Andrews chooses NanoSight NTA system for exosomes characterization
The National Physical Laboratory uses NanoSight NTA system for nanoparticle characterization
King Abdullah University for Science & Technology uses NanoSight Characterization System to Aid their Water Desalination & Reuse Research Programs
NanoSight announces interactive webinar on September 9th on the Characterization of Protein Aggregation
The Forschungszentrum Dresden-Rossendorf chooses NanoSight to characterize magnetic nanoparticles
NanoSight holds first European users meeting on nanoparticle characterization in Langen, Germany
NanoSight reports 100th third party peer reviewed paper is published; NTA is now firmly established worldwide